Amundi raised its position in shares of Cameco Co. (NYSE:CCJ – Free Report) (TSE:CCO) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,156,893 shares of the basic materials company’s stock after purchasing an additional 32,825 shares during the period. Amundi owned approximately 0.50% of Cameco worth $110,821,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in CCJ. CIBC Asset Management Inc grew its stake in shares of Cameco by 58.0% during the third quarter. CIBC Asset Management Inc now owns 3,777,866 shares of the basic materials company’s stock valued at $181,382,000 after buying an additional 1,386,639 shares during the last quarter. Segra Capital Management LLC bought a new position in shares of Cameco during the third quarter valued at about $53,013,000. Fred Alger Management LLC grew its stake in shares of Cameco by 99.7% during the third quarter. Fred Alger Management LLC now owns 1,680,259 shares of the basic materials company’s stock valued at $80,249,000 after buying an additional 839,077 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Cameco during the fourth quarter valued at about $34,440,000. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Cameco by 44.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,151,105 shares of the basic materials company’s stock valued at $102,737,000 after buying an additional 664,828 shares during the last quarter. Hedge funds and other institutional investors own 70.21% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on CCJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Cameco in a research note on Tuesday, March 4th. StockNews.com raised Cameco from a “sell” rating to a “hold” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Cameco has a consensus rating of “Buy” and a consensus price target of $71.25.
Cameco Stock Performance
Cameco stock opened at $40.72 on Tuesday. The stock has a market cap of $17.72 billion, a price-to-earnings ratio of 145.42 and a beta of 1.04. Cameco Co. has a fifty-two week low of $35.43 and a fifty-two week high of $62.55. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.26 and a current ratio of 2.88. The stock’s 50 day simple moving average is $48.59 and its two-hundred day simple moving average is $50.02.
Cameco (NYSE:CCJ – Get Free Report) (TSE:CCO) last released its quarterly earnings data on Thursday, February 20th. The basic materials company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. The business had revenue of $845.54 million for the quarter, compared to analysts’ expectations of $1.09 billion. Cameco had a return on equity of 4.34% and a net margin of 5.39%. As a group, analysts expect that Cameco Co. will post 1.27 earnings per share for the current fiscal year.
Cameco Company Profile
Cameco Corporation provides uranium for the generation of electricity. It operates through Uranium, Fuel Services, Westinghouse segments. The Uranium segment is involved in the exploration for, mining, and milling, purchase, and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate, as well as the purchase and sale of conversion services.
See Also
- Five stocks we like better than Cameco
- Conference Calls and Individual Investors
- How to Protect Your Portfolio When Inflation Is Rising
- Stock Splits, Do They Really Impact Investors?
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Cameco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cameco and related companies with MarketBeat.com's FREE daily email newsletter.